Form 4: ADC Therapeutics CEO Ameet Mallik Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
CEO Ameet Mallik disposed of 26,758 common shares of ADC Therapeutics SA to cover tax obligations related to vesting restricted share units.
Summary
- On May 6, 2025, Ameet Mallik, CEO of ADC Therapeutics SA, disposed of 26,758 common shares.
- The shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of previously granted restricted share units.
- The transaction price was $1.29 per share.
- Following the transaction, Mallik beneficially owns 1,552,247 common shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports a routine transaction for tax purposes.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 05/06/2025 | Date of transaction: Disposal of common shares. |
| 05/08/2025 | Date of signature on the report. |
Keywords
ADC Therapeutics, Ameet Mallik, Form 4, Share Disposal, Tax Obligations, Restricted Share Units, ADCT, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.